Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06645977
Recruiting Observational

Patients With Interstitial Lung Disease

NCT06645977 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2024-04-01
Last updated
2024-10-17

Condition(s) studied

Interstitial Lung Disease

Study summary

Prospective monocentric collection of data from adult patients with interstitial lung disease (ILD), to provide real-world data on current patient management at the ILD clinic.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>= 18 years * Diagnosis of ILD, according to international guidelines. Exclusion Criteria: * Inability to give informed consent.

Primary outcome measure(s)

  • Prevalce ILD — 5 years

Trial sites (1)

FacilityCityRegionStatus
Fondazione Policlinico Universitario Agostino Gemelli Rome RM Recruiting

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

The Management of Asymptomatic Carotid Stenosis Recruiting
Modular Neurological Examination for Early Risk Detection Active, not recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. Recruiting
BRCA Mutation Carriers' Platform a Multicenter Study Recruiting
Superior Cervical Ganglion in Parkinson's Disease Recruiting

Other trials for the same condition

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) Active, not recruiting
A Study of Mosliciguat in PH-ILD Active, not recruiting
Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases Recruiting
Ultrasound and Respiratory Physiological Signals in Lung Diseases Recruiting
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06645977 on ClinicalTrials.gov ↗ ← All trials in Italy